# Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

> **NCT05730699** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 105 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders

## Interventions

- **BIOLOGICAL:** divozilimab

## Key facts

- **NCT ID:** NCT05730699
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-12
- **Primary completion:** 2025-01
- **Final completion:** 2026-09
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05730699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05730699, "Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05730699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*